<?xml version='1.0' encoding='utf-8'?>
<document id="16735959"><sentence text="Meglitinide analogues: a review of clinical data focused on recent trials."><entity charOffset="0-11" id="DDI-PubMed.16735959.s1.e0" text="Meglitinide" /></sentence><sentence text="Glinides represent a chemically heterogeneous new class of insulin-secreting agents characterized by a rapid onset and short duration of action" /><sentence text=" They act by closure of the ATP-dependant K channel" /><sentence text=" Repaglinide, the only glinide available in France, has an equivalent HbA1c lowering effect to conventional sulfonylureas but reduces predominantly postprandial glucose levels"><entity charOffset="1-12" id="DDI-PubMed.16735959.s4.e0" text="Repaglinide" /><entity charOffset="23-30" id="DDI-PubMed.16735959.s4.e1" text="glinide" /><entity charOffset="108-121" id="DDI-PubMed.16735959.s4.e2" text="sulfonylureas" /><entity charOffset="161-168" id="DDI-PubMed.16735959.s4.e3" text="glucose" /><pair ddi="false" e1="DDI-PubMed.16735959.s4.e0" e2="DDI-PubMed.16735959.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16735959.s4.e0" e2="DDI-PubMed.16735959.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16735959.s4.e0" e2="DDI-PubMed.16735959.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16735959.s4.e0" e2="DDI-PubMed.16735959.s4.e3" /><pair ddi="false" e1="DDI-PubMed.16735959.s4.e1" e2="DDI-PubMed.16735959.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16735959.s4.e1" e2="DDI-PubMed.16735959.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16735959.s4.e1" e2="DDI-PubMed.16735959.s4.e3" /><pair ddi="false" e1="DDI-PubMed.16735959.s4.e2" e2="DDI-PubMed.16735959.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16735959.s4.e2" e2="DDI-PubMed.16735959.s4.e3" /></sentence><sentence text=" Several studies indicate a decreased risk of hypoglycaemias, particularly nocturnal or in case of a shift or omission of a meal" /><sentence text=" This drug appears particularly useful in early stage type 2 diabetes or in combination with metformin"><entity charOffset="93-102" id="DDI-PubMed.16735959.s6.e0" text="metformin" /></sentence><sentence text=" The only significant drug-drug interaction concerns gemfibrozil"><entity charOffset="53-64" id="DDI-PubMed.16735959.s7.e0" text="gemfibrozil" /></sentence><sentence text=" Due to its hepatic metabolism and biliary elimination, repaglinide can be used in patients with renal insufficiency"><entity charOffset="56-67" id="DDI-PubMed.16735959.s8.e0" text="repaglinide" /></sentence><sentence text=" Nateglinide has a even shorter duration of action and has almost no effect on fasting plasma glucose levels"><entity charOffset="1-12" id="DDI-PubMed.16735959.s9.e0" text="Nateglinide" /><entity charOffset="94-101" id="DDI-PubMed.16735959.s9.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.16735959.s9.e0" e2="DDI-PubMed.16735959.s9.e0" /><pair ddi="false" e1="DDI-PubMed.16735959.s9.e0" e2="DDI-PubMed.16735959.s9.e1" /></sentence><sentence text=" For this reason, this drug is only indicated in combination with metformin in the countries where it is licensed"><entity charOffset="66-75" id="DDI-PubMed.16735959.s10.e0" text="metformin" /></sentence><sentence text=" Several experimental data suggest that glinides could preserve B cell function over time better than hypoglycaemic sulfonylureas, and that the improvement of post-prandial glucose levels could exert a long term protective cardiovascular effect"><entity charOffset="173-180" id="DDI-PubMed.16735959.s11.e0" text="glucose" /></sentence><sentence text="" /></document>